CapsoVision Q1 revenue flat at $2.8M; gross margin slides to 48% on tariffs

CapsoVision, Inc

2026-Q1 EPS reported -$0.15 revenue$2,792,000

Total revenue $2.8M, flat YoY; capsule volume down 3% offset by higher ASP.
Gross margin 48% vs 54% YoY due to impact of U.S. trade policies and tariffs.
Operating expenses $8.4M, up $1.5M from CMOS sensor development with Canon and Colon clinical trials.
Cash $17.9M; completed $14M PIPE financing on March 16, 2026.
Pipeline: AI-assisted reading feature on track for mid-2026 FDA clearance; CapsoCam Colon 510(k) submission Q3 2026; pancreatic cancer study enrolled first patient May 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CapsoVision, Inc reported the fiscal quarter ended March 31, 2026 results: revenue $2.8 million.

Period: the fiscal quarter ended March 31, 2026
Revenue: $2.8 million
Result: reported results

Exact text from the filing

and AI-enabled capsule endoscopy solutions, today reported financial results for its first quarter ended March 31, 2026. Recent Highlights • Delivered first quarter revenue of $2.8 million, stable compared to the first quarter of 2025. • Existing customers continued to expand clinical use of CapsoCam Plus® for small bowel disease detection, while procedure volume

View on SEC.gov

Browse all earnings releases →

CapsoVision, Inc filing history →

Source: SEC EDGAR

accession 0001378325-26-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.